Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Norketotifen (NKT) in the Treatment of Acute Uncomplicated Influenza-like Illness (ILI)

NCT04043923 is registered in ClinicalTrials.gov with Emergo Therapeutics, Inc. as lead sponsor.

NCT NCT04043923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04043923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Norketotifen (NKT) in the Treatment of Acute Uncomplicated Influenza-like Illness (ILI)
Lead sponsor
Emergo Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 21, 2019
Completion date
April 20, 2020
Enrollment
238 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

influenza -like illness